Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: Effects on survival time, tumor growth, and tumor neovascularization

E. Corsini, M. Gelati, C. Calatozzolo, G. Alessandri, S. Frigerio, M. De Francesco, C. Poiesi, E. Parati, D. Croci, A. Boiardi, A. Salmaggi

Research output: Contribution to journalArticle


High-grade gliomas are aggressive tumors of the central nervous system characterized by endothelial cell proliferation and a high degree of vascularity. Conventional antitumoral treatments (i.e., surgery, radiotherapy, and chemotherapy) do not achieve satisfactory results (median survival in glioblastoma 12-18 months). It has been suggested that immunotherapy with xenogenic endothelial cells could slow tumor growth rate in a number of tumors in a murine model, but the study did not include gliomas. In experiments performed in our laboratory, vaccination with proliferating bovine aortic endothelium increased survival time in Fischer rats inoculated intracerebrally with 9L. Immunotherapy was also able to reduce the growth of subcutaneously injected 9L gliosarcoma cells in Fischer rats and to decrease microvessel density within the tumors, in the absence of major organ toxicity. Immunoglobulins (Ig) in the sera from vaccinated rats stained bovine aortic endothelium as well as human umbilical vein endothelium in active proliferation. Moreover, immune sera from immunized rats stained microvessels of human malignant glioma specimens and vessels of intracerebrally implanted tumors. Two proteins of MW of 11 and 19 kDa were identified by Western blot as targets of Ig elicited by vaccination. A possible future development is to select peptides/proteins suitable for vaccination in humans, avoiding the biohazards connected with xenogenic whole-cell vaccination.

Original languageEnglish
Pages (from-to)955-962
Number of pages8
JournalCancer Immunology, Immunotherapy
Issue number11
Publication statusPublished - Nov 2004



  • Glioma
  • Immunotherapy
  • Neoangiogenesis

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this